drugset / Trial / NCT04607148
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Non-randomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of intravitreal (ITV) injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who completed the parent study (NCT03972709/GR40973).
Timeline
- Start
- 2020-11-16
- Primary completion
- 2022-11-14
- Completion
- 2022-11-14
Outcome
Outcome not reported
Stopped: “The benefit to risk balance did not support further treatment with galegenimab (FHTR2163).”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galegenimab | Monoclonal antibody | 10 mg | Intravitreal |
| Subject | Galegenimab | Monoclonal antibody | 20 mg | Intravitreal |